Stockreport

AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says [Yahoo! Finance]

AbCellera Biologics Inc. - Common Shares  (ABCL) 
PDF roughly $1 billion into an end-to-end antibody discovery, development and manufacturing platform and is now advancing internally selected targets. ABCL635 , an NK3R-ta [Read more]